A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade®, ICL670) Is Well Tolerated and Reduces Iron Burden.
Year: 2005
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Blood
Authors: E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks
Institutions: Howard University, University College London, The Barbara Ann Karmanos Cancer Institute, Children's Hospital Los Angeles, Emory University, Children's Healthcare of Atlanta, Baylor College of Medicine, Hôpital Intercommunal de Créteil, Ente Ospedaliero Ospedali Galliera, Novartis (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W190357846